Risk factors for prostate cancer: A review
More details
Hide details
1
Department of Rehabilitation, Faculty of Health Sciences in Katowice, Medical University of Silesia, Katowice, Poland
2
Department of Public Health, Faculty of Public Health in Bytom, Medical University of Silesia, Katowice, Poland
3
Department of Health Sciences, Jan Długosz University of Humanities and Natural Sciences in Częstochowa, Poland
Corresponding author
Tomasz Jurys
Katedra i Klinika Rehabilitacji, Wydział Nauk o Zdrowiu w Katowicach ŚUM, ul. Ziołowa 45,
40-635 Katowice
Ann. Acad. Med. Siles. 2026;80:212-218
KEYWORDS
TOPICS
ABSTRACT
Prostate cancer is one of the most frequently diagnosed malignancies in men worldwide. Geographic variations in incidence and mortality suggest a significant role of both genetic and environmental factors. A literature review was conducted, covering 220 scientific articles published in the last 10 years, among the databases PubMed, Embase, and Cochrane Central. The analysis focused on risk factors for prostate cancer, including age, genetic predisposition, lifestyle, diet, comorbidities, and pharmacotherapy. The non-modifiable risk factors were age over 50, positive family history, and genetic predispositions (e.g., BRCA2 or HOXB13 mutations). Among the modifiable factors, obesity and diets rich in saturated fats, red and processed meat, and dairy products were associated with increased risk. Conversely, the consumption of tomatoes, soy products, coffee, and tea was linked to reduced risk. Associations with physical activity, alcohol consumption, smoking, and the use of metabolic drugs remain inconclusive. Identifying prostate cancer risk factors is crucial for the development of preventive strategies. Promoting healthy lifestyle habits, maintaining proper body weight, and adopting a balanced diet may significantly reduce risk. Although many factors are non-modifiable, their recognition enables more personalized prevention and diagnostic approaches.
REFERENCES (40)
1.
Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021; doi: 10.1002/ijc.33588. Online ahead of print.
2.
Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 Update on Prostate Cancer Epidemiology and Risk Factors – A Systematic Review. Eur Urol. 2023;84(2):191–206. doi: 10.1016/j.eururo.2023.04.021.
3.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660.
4.
Cirne F, Kappel C, Zhou S, Mukherjee SD, Dehghan M, Petropoulos JA, et al. Modifiable risk factors for prostate cancer in low- and lower-middle-income countries: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2022;25(3):453–462. doi: 10.1038/s41391-022-00570-1.
5.
Mottet N, Cornford P, van den Bergh RCN, Briers E, Eberli D, De Meerleer G, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. EAU Guidelines Office; 2023.
6.
Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules. 2022;27(17):5730. doi: 10.3390/molecules27175730.
7.
Leslie SW, Soon-Sutton TL, Skelton WP. Prostate Cancer. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 29261872.
8.
Gacci M, Russo GI, De Nunzio C, Sebastianelli A, Salvi M, Vignozzi L, et al. Meta-analysis of metabolic syndrome and prostate cancer. Prostate Cancer Prostatic Dis. 2017;20(2):146–155. doi: 10.1038/pcan.2017.1.
9.
Gandaglia G, Leni R, Bray F, Fleshner N, Freedland SJ, Kibel A, et al. Epidemiology and prevention of prostate cancer. Eur Urol Oncol. 2021;4(6):877–892. doi: 10.1016/j.euo.2021.09.006.
10.
Siegel DA, O’Neil ME, Richards TB, Dowling NF, Weir HK. Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity — United States, 2001–2017. MMWR Morb Mortal Wkly Rep. 2020;69(41):1473–1480. doi: 10.15585/mmwr.mm6941a1.
11.
Lophatananon A, Stewart-Brown S, Kote-Jarai Z, Olama AAA, Garcia SB, Neal DE, et al. Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. Br J Cancer. 2017;117(5):734-743. doi: 10.1038/bjc.2017.231. Erratum in: Br J Cancer. 2018;118(6):e16. doi: 10.1038/bjc.2018.6.
12.
Karlsson Q, Brook MN, Dadaev T, Wakerell S, Saunders EJ, Muir K, et al. Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. Eur Urol Oncol. 2021;4(4):570–579. doi: 10.1016/j.euo.2020.12.001.
13.
Ren W, Zhu Y. Causal associations between the presence of prostate cancer or testosterone levels and bladder cancer risk: a Mendelian Randomization study. Clin Genitourin Cancer. 2025;23(3):102334. doi: 10.1016/j.clgc.2025.102334.
14.
Vallières E, Mésidor M, Roy-Gagnon MH, Richard H, Parent MÉ. General and abdominal obesity trajectories across adulthood, and risk of prostate cancer: results from the PROtEuS study, Montreal, Canada. Cancer Causes Control. 2021;32(6):653–665. doi: 10.1007/s10552-021-01419-z.
15.
Alzahrani MA, Shakil Ahmad M, Alkhamees M, Aljuhayman A, Binsaleh S, Tiwari R, et al. Dietary protein intake and prostate cancer risk in adults: A systematic review and dose-response meta-analysis of prospective cohort studies. Complement Ther Med. 2022;70:102851. doi: 10.1016/j.ctim.2022.102851.
16.
Li J, Mao QQ. Legume intake and risk of prostate cancer: a meta-analysis of prospective cohort studies. Oncotarget. 2017;8(27):44776–44784. doi: 10.18632/oncotarget.16794.
17.
Parra-Soto S, Ahumada D, Petermann-Rocha F, Boonpoor J, Gallegos JL, Anderson J, et al. Association of meat, vegetarian, pescatarian and fish-poultry diets with risk of 19 cancer sites and all cancer: findings from the UK Biobank prospective cohort study and meta-analysis. BMC Med. 2022;20(1):79. doi: 10.1186/s12916-022-02257-9.
18.
Watling CZ, Schmidt JA, Dunneram Y, Tong TYN, Kelly RK, Knuppel A, et al. Risk of cancer in regular and low meat-eaters, fish-eaters, and vegetarians: a prospective analysis of UK Biobank participants. BMC Med. 2022;20(1):73. doi: 10.1186/s12916-022-02256-w.
19.
Chen X, Zhao Y, Tao Z, Wang K. Coffee consumption and risk of prostate cancer: a systematic review and meta-analysis. BMJ Open. 2021;11(2):e038902. doi: 10.1136/bmjopen-2020-038902.
20.
Gao J, Wei W, Wang G, Zhou H, Fu Y, Liu N. Circulating vitamin D concentration and risk of prostate cancer: a dose-response meta-analysis of prospective studies. Ther Clin Risk Manag. 2018;14:95–104. doi: 10.2147/TCRM.S149325.
21.
Stroomberg HV, Vojdeman FJ, Madsen CM, Helgstrand JT, Schwarz P, Heegaard AM, et al. Vitamin D levels and the risk of prostate cancer and prostate cancer mortality. Acta Oncol. 2021;60(3):316–322. doi: 10.1080/0284186X.2020.1837391.
22.
Jiang X, Dimou NL, Al-Dabhani K, Lewis SJ, Martin RM, Haycock PC, et al. Circulating vitamin D concentrations and risk of breast and prostate cancer: a Mendelian randomization study. Int J Epidemiol. 2019;48(5):1416–1424. doi: 10.1093/ije/dyy284.
23.
Lawrence WR, Lim JE, Huang J, Weinstein SJ, Mӓnnistӧ S, Albanes D. A 28-year prospective analysis of serum vitamin E, vitamin E-related genetic variation and risk of prostate cancer. Prostate Cancer Prostatic Dis. 2022;25(3):553–560. doi: 10.1038/s41391-022-00511-y.
24.
Fraser GE, Jacobsen BK, Knutsen SF, Mashchak A, Lloren JI. Tomato consumption and intake of lycopene as predictors of the incidence of prostate cancer: the Adventist Health Study-2. Cancer Causes Control. 2020;31(4):341–351. doi: 10.1007/s10552-020-01279-z.
25.
Rumgay H, Murphy N, Ferrari P, Soerjomataram I. Alcohol and cancer: epidemiology and biological mechanisms. Nutrients. 2021;13(9):3173. doi: 10.3390/nu13093173.
26.
Hong S, Khil H, Lee DH, Keum N, Giovannucci EL. Alcohol consumption and the risk of prostate cancer: a dose-response meta-analysis. Nutrients. 2020;12(8):2188. doi: 10.3390/nu12082188.
27.
Al-Fayez S, El-Metwally A. Cigarette smoking and prostate cancer: A systematic review and meta-analysis of prospective cohort studies. Tob Induc Dis. 2023;21:19. doi: 10.18332/tid/157231.
28.
Murray JM, Coleman HG, Hunter RF. Physical activity and cancer risk: Findings from the UK Biobank, a large prospective cohort study. Cancer Epidemiol. 2020;68:101780. doi: 10.1016/j.canep.2020.101780.
29.
Brassetti A, Cacciatore L, Bove AM, Anceschi U, Proietti F, Misuraca L, et al. The impact of physical activity on the outcomes of active surveillance in prostate cancer patients: A scoping review. Cancers (Basel). 2024;16(3):630. doi: 10.3390/cancers16030630.
30.
Suh J, Shin TJ, You D, Jeong IG, Hong JH, Kim CS, et al. The association between serum lipid profile and the prostate cancer risk and aggressiveness. Front Oncol. 2023;13:1113226. doi: 10.3389/fonc.2023.1113226.
31.
Garrido MM, Marta JC, Ribeiro RM, Pinheiro LC, Guimarães JT. Serum lipids and prostate cancer. J Clin Lab Anal. 2021;35(4):e23705. doi: 10.1002/jcla.23705.
32.
Cui H, Wang Y, Yang S, He G, Jiang Z, Gang X, et al. Antidiabetic medications and the risk of prostate cancer in patients with diabetes mellitus: A systematic review and meta-analysis. Pharmacol Res. 2022;177:106094. doi: 10.1016/j.phrs.2022.106094.
33.
Feng Z, Zhou X, Liu N, Wang J, Chen X, Xu X. Metformin use and prostate cancer risk: A meta-analysis of cohort studies. Medicine (Baltimore). 2019;98(12):e14955. doi: 10.1097/MD.0000000000014955.
34.
Drewa J, Lazar-Juszczak K, Adamowicz J, Juszczak K. May patients receiving GLP-1 agonists be at lower risk of prostate cancer aggressiveness and progression? Cancers (Basel). 2025;17(9):1576. doi: 10.3390/cancers17091576.
35.
Zhu D, Toker M, Shyr W, Fram E, Watts KL, Agalliu I. Association of obesity and diabetes with prostate cancer risk groups in a multiethnic population. Clin Genitourin Cancer. 2022;20(3):299–299.e10. doi: 10.1016/j.clgc.2022.01.016.
36.
Lopez DS, Polychronopoulou E, Tsilidis KK, Khera M, Su LJ, Fowke JH, et al. Independent and joint effects of testosterone replacement therapy and statins use on the risk of prostate cancer among White, Black, and Hispanic men. Cancer Prev Res. 2021;14(7):719–728. doi: 10.1158/1940-6207.CAPR-21-0040.
37.
Watts EL, Appleby PN, Perez-Cornago A, Bueno-de-Mesquita HB, Chan JM, Chen C, et al. Low Free Testosterone and Prostate Cancer Risk: A Collaborative Analysis of 20 Prospective Studies. Eur Urol. 2018;74(5):585–594. doi: 10.1016/j.eururo.2018.07.024.
38.
Khan S, Caldwell J, Wilson KM, Gonzales-Feliciano AG, Peisch S, Pernar CH, et al. Baldness and risk of prostate cancer in the Health Professionals Follow-up Study. Cancer Epidemiol Biomarkers Prev. 2020;29(6):1229–1236. doi: 10.1158/1055-9965.EPI-19-1236.
39.
Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, et al. Prostate cancer. Nat Rev Dis Primers. 2021;7(1):9. doi: 10.1038/s41572-020-00243-0.
40.
Miller EA, Pinsky PF. Examining the relationship between diabetes and prostate cancer through changes in screening guidelines. Cancer Causes Control. 2020;31(12):1105–1113. doi: 10.1007/s10552-020-01347-4.